Elicit: CD80/CD86 Blockade and T-Cell Dynamics

How does CD80/CD86 blockade by abatacept affect T-cell activation and tolerance?

Abstract

CD80/CD86 blockade by abatacept consistently reduces T-cell activation across multiple disease contexts through selective modulation of CD28-mediated costimulation. Treatment decreases expression of activation markers (CD38, ICOS, Ki-67) and reduces proliferation particularly in CD4+ T cells, with 7-10-fold fewer proliferating and activated effector memory CD4+ T cells observed in GVHD prevention. Abatacept shifts CD4+ compartments toward naive phenotypes while reducing central memory populations, with transcriptional analysis revealing decreased expression of genes regulating cell cycle and chromatin dynamics.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria:

Results

Characteristics of Included Studies

Study Full text retrieved? Disease context Study design Abatacept regimen Primary T-cell measures
J. Kremer et al., 2006 Yes Rheumatoid arthritis with inadequate methotrexate response Randomized, double-blind, placebo-controlled ~10 mg/kg IV monthly for 1 year Not specified
M. Weisman et al., 2006 No Active rheumatoid arthritis with inadequate methotrexate response Phase II trial 10 mg/kg or 2 mg/kg for 12 months Inflammatory biomarkers (IL-6, soluble IL-2 receptor)
Divya Koura et al., 2013 Yes Acute GVHD prevention during unrelated-donor HCT First-in-disease trial 10 mg/kg IV on days -1, +5, +14, +28 post-HCT Ki-67 proliferation, CD38/HLA-DR activation, FoxP3+ Tregs
M. Eichmann et al., 2020 No New-onset type 1 diabetes Clinical trial Not specified CD4+ and CD8+ naive and memory subsets by flow/mass cytometry
R. Alten, 2007 No Rheumatoid arthritis unresponsive to DMARDs or TNF-blockers Review of trials ~10 mg/kg at weeks 0, 2, 4, then every 4 weeks for 6-12 months Not specified
T. Orbán et al., 2014 Yes Recent-onset type 1 diabetes Phase 2 trial 10 mg/kg IV every 28 days for 24 months CM and naive CD4 T cells, CD4+CD25high Tregs, CD69 activation
A. Parulekar et al., 2013 No Mild atopic asthma Randomized, placebo-controlled, double-blind trial 3 months of treatment Naive vs. memory CD4+ T cells
B. Watkins et al., 2021 No Severe acute GVHD following unrelated-donor HCT Phase II trial, randomized and single-arm CNI/MTX plus abatacept, measured at day +100 and +180 T-cell activation (method not specified)
S. Glatigny et al., 2019 Yes Relapsing-remitting multiple sclerosis Phase II, double-blind, placebo-controlled trial Weeks 0, 2, 4, then every 4 weeks through week 24 Tfh and Treg frequency, CD38/ICOS activation, transcriptional profiling
M. Bonelli et al., 2016 No Rheumatoid arthritis In vivo clinical analysis and ex vivo experiments Not specified Treg frequency/function, CD95 expression, activation markers

Effects on T-cell Activation

Activation Marker Expression

Abatacept treatment reduced expression of multiple T-cell activation markers across disease contexts. In GVHD prevention, CD4+ T cells showed 7-fold fewer proliferating cells (Ki-67+) and 10-fold fewer activated cells (CD38+/HLA-DR+) at day +28 compared to controls, with effects concentrated in effector memory populations.

Proliferation and Cell Cycle Effects

Transcriptional analysis revealed that abatacept disrupted cell cycle and proliferation pathways in activated T cells. In multiple sclerosis patients, abatacept reduced expression of genes regulating cell cycle and chromatin dynamics during cell proliferation.

Effects on T-cell Subset Distribution

Study Context Naive T cells Memory T cells Specialized subsets Effect magnitude
T. Orbán et al., 2014 Type 1 diabetes Increased naive CD4+ T cells Decreased central memory CD4+ T cells Reduced CD4+CD25high Tregs Significant reduction in absolute CM numbers
M. Eichmann et al., 2020 Type 1 diabetes Ag-naive subsets increase Ag-experienced subsets decrease Not specified CD4+ affected, CD8+ not affected
A. Parulekar et al., 2013 Asthma Increased naive CD4+ T cells Decreased memory CD4+ T cells Not specified Not quantified
S. Glatigny et al., 2019 Multiple sclerosis No effect on CD45RA+ naive Tregs Decreased CD45RO+ memory Tregs Decreased Tfh frequency; reduced CD38+/ICOS+ activation Progressive Tfh decline
M. Bonelli et al., 2016 Rheumatoid arthritis Not specified Not specified Increased Treg numbers; diminished Treg suppressive function Not quantified

Effects on Regulatory T Cells and Tolerance

In rheumatoid arthritis, total Treg numbers increased, but functional suppression assays revealed diminished capacity to suppress responder T-cell proliferation. The results indicate that abatacept affects regulatory T cells differently depending on context.

Temporal Dynamics of Effects

Study Context Onset of activation effects Peak effects Reversibility Duration assessed
Divya Koura et al., 2013 GVHD Day +28 Day +28 Yes, effects diminished after treatment cessation Through day +100
T. Orbán et al., 2014 Type 1 diabetes Within first 6 months 6, 12, and 24 months Yes, returned to baseline 6 months post-treatment 30 months (24 + 6 follow-up)
S. Glatigny et al., 2019 Multiple sclerosis Treg changes at 4 weeks; Tfh at 16 weeks Not specified Yes, reversed upon discontinuation 52 weeks
J. Kremer et al., 2006 Rheumatoid arthritis By 6 months Up to 1 year Not assessed 1 year

Mechanistic Insights into Activation vs. Tolerance

Abatacept’s mechanism extends beyond simple CD80/CD86 blockade to affect multiple cellular processes. The selective decrease in activated (CD38+/ICOS+) Tfh and Treg cells indicated that abatacept preferentially affected cells requiring ongoing costimulation.

Study Quality and Limitations

Several factors affect interpretation of these findings across studies, including sample size limitations, confounding medications, and technical limitations in measurements.